Search

Pharma Mar SA

Fermé

73.9 -3.15

Résumé

Variation du prix de l'action

24h

Actuel

Min

73.55

Max

74

Chiffres clés

By Trading Economics

Revenu

27M

23M

Ventes

18M

56M

P/E

Moyenne du Secteur

32.604

37.461

BPA

1.33

Rendement du dividende

1.01

Marge bénéficiaire

41.41

Employés

500

EBITDA

27M

26M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+61.51% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.01%

2.33%

Prochains Résultats

30 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-86M

1.4B

Ouverture précédente

77.05

Clôture précédente

73.9

Score Technique

By Trading Central

Confiance

Bearish Evidence

Pharma Mar SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 oct. 2025, 18:41 UTC

Résultats

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct. 2025, 18:31 UTC

Résultats

Correction to Procter & Gamble to Focus on Innovation

24 oct. 2025, 16:25 UTC

Principaux Mouvements du Marché

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 oct. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct. 2025, 21:07 UTC

Résultats

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct. 2025, 20:58 UTC

Résultats

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 20:40 UTC

Résultats

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct. 2025, 20:24 UTC

Résultats

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:23 UTC

Résultats

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:13 UTC

Résultats

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct. 2025, 19:33 UTC

Résultats

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct. 2025, 18:52 UTC

Résultats

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:41 UTC

Résultats

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:03 UTC

Résultats

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct. 2025, 18:02 UTC

Résultats

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct. 2025, 16:57 UTC

Résultats

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct. 2025, 16:44 UTC

Market Talk
Résultats

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct. 2025, 16:39 UTC

Market Talk
Résultats

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct. 2025, 16:33 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:23 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 16:07 UTC

Résultats

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Pharma Mar SA prévision

Objectif de Prix

By TipRanks

61.51% hausse

Prévisions sur 12 Mois

Moyen 120.002 EUR  61.51%

Haut 120 EUR

Bas 120 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

72.75 / 74.3Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
help-icon Live chat